These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 29945203)

  • 1. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
    Gottlieb AB; Strand V; Kishimoto M; Mease P; Thaçi D; Birt J; Lee CH; Shuler CL; Lin CY; Gladman DD
    Rheumatology (Oxford); 2018 Oct; 57(10):1777-1788. PubMed ID: 29945203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
    J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.
    Kavanaugh A; Marzo-Ortega H; Vender R; Wei CC; Birt J; Adams DH; Benichou O; Lin CY; Nash P
    Clin Exp Rheumatol; 2019; 37(4):566-574. PubMed ID: 30557128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
    Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
    Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
    Chandran V; van der Heijde D; Fleischmann RM; Lespessailles E; Helliwell PS; Kameda H; Burgos-Vargas R; Erickson JS; Rathmann SS; Sprabery AT; Birt JA; Shuler CL; Gallo G
    Rheumatology (Oxford); 2020 Oct; 59(10):2774-2784. PubMed ID: 32031665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
    Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
    Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials.
    Tillett W; Lin CY; Trevelin Sprabery A; Birt JA; Kavanaugh A
    Clin Exp Rheumatol; 2020; 38(6):1227-1230. PubMed ID: 32452352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3.
    Leonardi CL; Blauvelt A; Sofen HL; Gooderham M; Augustin M; Burge R; Zhu B; Reich K
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1483-1490. PubMed ID: 28294430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
    Genovese MC; Combe B; Kremer JM; Tsai TF; Behrens F; Adams DH; Lee C; Kerr L; Nash P
    Rheumatology (Oxford); 2018 Nov; 57(11):2001-2011. PubMed ID: 30053162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
    Maksymowych WP; Bolce R; Gallo G; Seem E; Geneus VJ; Sandoval DM; Østergaard M; Tada K; Baraliakos X; Deodhar A; Gensler LS
    Rheumatology (Oxford); 2022 Nov; 61(11):4324-4334. PubMed ID: 35188180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
    Nash P; Kirkham B; Okada M; Rahman P; Combe B; Burmester GR; Adams DH; Kerr L; Lee C; Shuler CL; Genovese M;
    Lancet; 2017 Jun; 389(10086):2317-2327. PubMed ID: 28551073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
    Deodhar A; Poddubnyy D; Pacheco-Tena C; Salvarani C; Lespessailles E; Rahman P; Järvinen P; Sanchez-Burson J; Gaffney K; Lee EB; Krishnan E; Santisteban S; Li X; Zhao F; Carlier H; Reveille JD;
    Arthritis Rheumatol; 2019 Apr; 71(4):599-611. PubMed ID: 30343531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
    Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
    Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
    Blauvelt A; Papp KA; Sofen H; Augustin M; Yosipovitch G; Katoh N; Mrowietz U; Ohtsuki M; Poulin Y; Shrom D; Burge R; See K; Mallbris L; Gordon KB
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1004-1013. PubMed ID: 28190255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study.
    Coates LC; Pillai SG; Tahir H; Valter I; Chandran V; Kameda H; Okada M; Kerr L; Alves D; Park SY; Adams DH; Gallo G; Hufford MM; Hojnik M; Mease PJ; Kavanaugh A;
    Arthritis Rheumatol; 2021 Sep; 73(9):1663-1672. PubMed ID: 33682378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
    Armstrong AW; Lynde CW; McBride SR; Ståhle M; Edson-Heredia E; Zhu B; Amato D; Nikaï E; Yang FE; Gordon KB
    JAMA Dermatol; 2016 Jun; 152(6):661-9. PubMed ID: 26953848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.
    Guenther L; Warren RB; Cather JC; Sofen H; Poulin Y; Lebwohl M; Terui T; Potts Bleakman A; Zhu B; Burge R; Reich K; van de Kerkhof P
    J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1867-1875. PubMed ID: 28573743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).
    Imafuku S; Torisu-Itakura H; Nishikawa A; Zhao F; Cameron GS;
    J Dermatol; 2017 Nov; 44(11):1285-1290. PubMed ID: 28635026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study.
    Yosipovitch G; Foley P; Ryan C; Cather JC; Meeuwis KA; Burge R; Bleakman AP; Lin CY; Malatestinic W; Gottlieb A
    J Sex Med; 2018 Nov; 15(11):1645-1652. PubMed ID: 30415816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.
    Husni ME; Mease PJ; Merola JF; Tillett W; Goldammer N; Ink B; Coarse J; Lambert J; Taieb V; Gladman DD
    RMD Open; 2024 Sep; 10(3):. PubMed ID: 39313302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.